Profile data is unavailable for this security.
About the company
Xbrane Biopharma AB, formerly Xbrane Bioscience AB, is a Sweden-based provider of biotechnology research and development services. It develops biogenerics for injectable slow release drugs and high-yield protein expression technology for the development of biosimilars. The Company's main products are Sperotide, a generic on the originator drug marketed under the trademarks Decapeptyl, Trelstar and Pamorelin, as well as Xlucane, a biosimilar on the originator drug sold under the trademark Lucentis.
- Revenue in SEK (TTM)191.89m
- Net income in SEK-340.89m
- Incorporated2008
- Employees71.00
- LocationXbrane Biopharma ABRetzius Vag 8SOLNA 171 65SwedenSWE
- Phone+46 855905600
- Websitehttps://xbrane.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Exact Therapeutics AS | 0.00 | -46.92m | 155.71m | 8.00 | -- | 3.56 | -- | -- | -1.51 | -1.51 | 0.00 | 1.41 | 0.00 | -- | -- | -- | -67.21 | -40.21 | -86.14 | -45.67 | -- | -- | -- | -- | -- | -16,578.57 | 0.0258 | -- | -- | -- | -20.52 | -- | -- | -- |
| AlzeCure Pharma AB | 0.00 | -35.87m | 176.15m | 11.00 | -- | 4.31 | -- | -- | -0.5371 | -0.5371 | 0.00 | 0.4625 | 0.00 | -- | -- | 0.00 | -75.21 | -52.78 | -89.05 | -57.01 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 33.91 | -- | -- | -- |
| Lumito AB (publ) | 17.00k | -26.38m | 184.38m | 14.00 | -- | 1.72 | -- | 10,846.03 | -0.1268 | -0.1268 | 0.00008 | 0.4598 | 0.0001 | -- | 0.0096 | 1,133.33 | -20.54 | -20.77 | -23.68 | -22.38 | 44,594.29 | -- | -155,169.10 | -- | 1.32 | -24.40 | 0.1569 | -- | -- | -- | 4.56 | -- | -- | -- |
| Biosergen AB | 0.00 | -26.60m | 193.17m | 2.00 | -- | 12.49 | -- | -- | -0.286 | -0.286 | 0.00 | 0.0557 | 0.00 | -- | -- | 0.00 | -145.58 | -- | -216.30 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 32.25 | -- | -- | -- |
| Acousort AB | 3.44m | -19.30m | 203.85m | -- | -- | 13.33 | -- | 59.28 | -1.33 | -1.33 | 0.2379 | 1.02 | 0.1461 | 4.08 | 1.96 | -- | -81.99 | -48.62 | -137.70 | -69.77 | -159.41 | -68.05 | -561.21 | -299.58 | 1.91 | -- | 0.00 | -- | 11.51 | 38.81 | -24.01 | -- | -- | -- |
| SenzaGen AB | 55.29m | -20.60m | 215.38m | 32.00 | -- | 2.35 | -- | 3.90 | -0.8299 | -0.8299 | 2.23 | 3.11 | 0.5019 | 3.32 | 5.80 | 1,626,029.00 | -18.70 | -25.84 | -23.34 | -29.85 | 71.63 | 68.62 | -37.27 | -132.29 | 2.76 | -51.34 | 0.0443 | -- | 19.39 | 90.32 | 11.30 | -- | -21.10 | -- |
| Biovica International AB | 7.25m | -115.45m | 227.00m | 27.00 | -- | 2.54 | -- | 31.31 | -1.73 | -1.73 | 0.1055 | 1.06 | 0.0584 | 17.30 | 4.76 | 226,593.80 | -92.98 | -51.94 | -110.37 | -58.18 | -394.72 | -576.01 | -1,592.15 | -2,217.41 | 3.47 | -- | 0.0721 | -- | 115.49 | 19.39 | -12.97 | -- | -54.31 | -- |
| Thor Medical ASA | 0.00 | -18.02m | 232.54m | 1.00 | -- | 0.9214 | -- | -- | -0.0873 | 0.021 | 0.00 | 1.11 | 0.00 | -- | -- | 0.00 | -9.82 | -79.17 | -10.54 | -113.94 | -- | -- | -- | -- | -- | -- | 0.0035 | -- | -- | -- | -- | -- | -- | -- |
| Kancera AB | 0.00 | -53.07m | 233.89m | 5.00 | -- | 2.82 | -- | -- | -0.5955 | -0.5955 | 0.00 | 0.6849 | 0.00 | -- | -- | 0.00 | -56.73 | -54.82 | -66.40 | -66.21 | -- | 96.28 | -- | -7,249.06 | -- | -- | 0.00 | -- | -- | -- | -23.64 | -- | -- | -- |
| Xbrane Biopharma AB | 191.89m | -340.89m | 238.60m | 71.00 | -- | 0.7835 | -- | 1.24 | -1.01 | -1.26 | 0.3403 | 0.1991 | 0.209 | 0.7028 | 24.13 | 2,063,301.00 | -37.14 | -40.98 | -66.96 | -67.24 | 43.32 | -- | -177.65 | -364.40 | 1.07 | -20.51 | 0.357 | -- | 314.33 | 63.42 | -91.10 | -- | 60.02 | -- |
| Ascelia Pharma AB | 0.00 | -61.78m | 240.20m | 13.00 | -- | 2.62 | -- | -- | -1.26 | -1.26 | 0.00 | 0.9554 | 0.00 | -- | -- | 0.00 | -52.75 | -- | -65.92 | -- | -- | -- | -- | -- | -- | -40.42 | 0.4167 | -- | -- | -- | 16.72 | -- | -- | -- |
| Intervacc AB | 9.78m | -102.66m | 275.68m | 15.00 | -- | 1.36 | -- | 28.19 | -1.36 | -1.36 | 0.1291 | 2.68 | 0.0355 | 3.19 | 1.62 | 651,933.30 | -37.23 | -17.62 | -40.38 | -18.77 | -551.10 | -243.59 | -1,049.76 | -626.90 | 2.90 | -- | 0.0006 | -- | -17.23 | -25.79 | -60.31 | -- | -38.72 | -- |
| Xintela AB | 381.00k | -40.83m | 287.22m | -- | -- | -- | -- | 753.87 | -0.0817 | -0.0817 | 0.0008 | -0.0319 | 0.0306 | -- | 0.0493 | -- | -327.65 | -181.06 | -- | -391.61 | 100.00 | -- | -10,717.06 | -235,894.00 | -- | -203.91 | -- | -- | -- | -45.54 | 18.32 | -- | -61.47 | -- |
| Annexin Pharmaceuticals AB (publ) | 0.00 | -52.36m | 291.01m | 4.00 | -- | 8.08 | -- | -- | -0.1873 | -0.1873 | 0.00 | 0.0676 | 0.00 | -- | -- | 0.00 | -162.59 | -125.42 | -220.41 | -151.33 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -8.17 | -- | -- | -- |
| Abliva AB | 137.00k | -102.13m | 295.62m | 6.00 | -- | 2.87 | -- | 2,157.81 | -0.0928 | -0.0928 | 0.0001 | 0.0638 | 0.0013 | -- | 0.0062 | -- | -93.81 | -74.59 | -103.87 | -86.98 | -35,826.28 | -- | -74,542.34 | -65,958.89 | -- | -- | 0.00 | -- | 341.94 | 93.89 | -12.02 | -- | -19.74 | -- |
Data as of Sep 20 2024. Currency figures normalised to Xbrane Biopharma AB's reporting currency: Swedish Krona SEK
6.33%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Handelsbanken Fonder ABas of 31 Aug 2024 | 51.94m | 3.40% |
| Swedbank Robur Fonder ABas of 29 May 2024 | 15.20m | 0.99% |
| Teknik Innovation Norden Fonder ABas of 31 Dec 2022 | 13.70m | 0.90% |
| SEB Investment Management ABas of 30 Aug 2024 | 7.60m | 0.50% |
| FCG Fonder ABas of 30 Aug 2024 | 5.17m | 0.34% |
| Storebrand Asset Management ASas of 31 Aug 2024 | 1.83m | 0.12% |
| Skandia Investment Management ABas of 31 Jul 2024 | 1.13m | 0.07% |
| SSgA Funds Management, Inc.as of 05 Sep 2024 | 104.82k | 0.01% |
| Danske Bank A/S (Investment Management)as of 31 Aug 2024 | 66.66k | 0.00% |
| Rockbridge TFIas of 31 Dec 2023 | 17.64k | 0.00% |
More ▼
Data from 31 Dec 2022 - 31 Aug 2024Source: FactSet Research Systems Inc.
